{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:42:07Z","timestamp":1792600927492,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T00:00:00Z","timestamp":1719360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T00:00:00Z","timestamp":1719360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004748","name":"Mashhad University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Nonalcoholic fatty liver disease (NAFLD) is a common dietary disorder caused by fatty changes in the liver parenchyma and hepatocytes without alcohol consumption. The present study aimed to investigate the prevalence, characteristics, and risk factors of NAFLD in the Mashhad Persian Cohort Study population.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>The present population-based cross-sectional study included all PERSIAN Organizational Cohort study in Mashhad University of Medical Sciences (POCM), Mashhad, Iran by census sampling method. Eligible participants were divided into two groups due to their NAFLD condition (NAFLD positive or NAFLD negative). All enrolled participants were evaluated based on their clinical aspects, anthropometric measures, laboratory tests, and ultrasound features. Statistical analysis was conducted using SPSS software version 16 (SPSS Inc., Chicago, USA \u2013version 16). A P-value less than 0.05 was considered as the significance level.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 1198 individuals were included in the study, of which 638 (53.3%) were male and the rest were female. The mean age of the participants was 46.89\u2009\u00b1\u20098.98 years. A total of 246 patients (20.53%) were NAFLD positive, of which 122 (49.59%) were in grade 1, 112 (45.52%) were in grade 2, and 12 (4.87%) were in grade 3. The prevalence of fatty liver was significantly higher in males than in females (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). There were significant differences between NAFLD positive and NAFLD negative participants in terms of having a history of hypertension (<jats:italic>P<\/jats:italic>\u2009=\u20090.044), body mass index (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), body fat percentage (<jats:italic>P<\/jats:italic>\u2009=\u20090.001), waist circumference (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), liver craniocaudal length (<jats:italic>P<\/jats:italic>\u2009=\u20090.012), fasting blood sugar (FBS) (<jats:italic>P<\/jats:italic>\u2009=\u20090.047), aspartate aminotransferase (AST) (<jats:italic>P<\/jats:italic>\u2009=\u20090.007), and alanine aminotransferase (ALT) (<jats:italic>P<\/jats:italic>\u2009=\u20090.001). Further analysis revealed a strong significant association between BMI, previous history of hypertension, higher levels of serum ALT, and NAFLD (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>It can be concluded that ultrasound findings accompanied by laboratory AST and ALT level enzymes could be a cost-benefit approach for NAFLD early diagnosis. The craniocaudal size of the liver could be a beneficent marker for estimating the severity of the disease; however, more studies are recommended to evaluate this variable for future practice against the issue.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12876-024-03302-y","type":"journal-article","created":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T12:02:01Z","timestamp":1719403321000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Prevalence, characteristics, and risk factors of non-alcoholic fatty liver disease in North East of Iran: a population-based study"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1071-7983","authenticated-orcid":false,"given":"Mina","family":"AkbariRad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0772-8462","authenticated-orcid":false,"given":"Masoud","family":"Pezeshki Rad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadi","family":"Nobakht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3892-5047","authenticated-orcid":false,"given":"AmirAli","family":"Moodi Ghalibaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdollah","family":"Firoozi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashkan","family":"Torshizian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Reza","family":"Bina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Beheshti Namdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoumeh","family":"Sadeghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,26]]},"reference":[{"issue":"1","key":"3302_CR1","first-page":"6","volume":"26","author":"A Hormati","year":"2021","unstructured":"Hormati A, Rezvan S, Matlob RK, Ahmadpour S, Matlob SK. Epidemiology and risk factor of non-alcoholic fatty liver diseases in Iran and worldwide: a literature review. GOVARESH. 2021;26(1):6\u201316.","journal-title":"GOVARESH"},{"key":"3302_CR2","doi-asserted-by":"crossref","unstructured":"Zeng J, Qin L, Jin Q, Yang R-X, Ning G, Su Q, et al. Prevalence and characteristics of MAFLD in Chinese adults aged 40 years or older: a community-based study. Hepatobiliary & Pancreatic Diseases International; 2022.","DOI":"10.1016\/j.hbpd.2022.01.006"},{"key":"3302_CR3","doi-asserted-by":"crossref","unstructured":"Golabi P, Otgonsuren M, de Avila L, Sayiner M, Rafiq N, Younossi ZM. Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD). Medicine. 2018;97(13).","DOI":"10.1097\/MD.0000000000010214"},{"issue":"5","key":"3302_CR4","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/apt.15163","volume":"49","author":"S Sookoian","year":"2019","unstructured":"Sookoian S, Pirola CJ. Shared disease mechanisms between non-alcoholic fatty liver disease and metabolic syndrome\u2013translating knowledge from systems biology to the bedside. Aliment Pharmacol Ther. 2019;49(5):516\u201327.","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"3302_CR5","first-page":"1131","volume":"26","author":"D Esmaealzadeh","year":"2023","unstructured":"Esmaealzadeh D, Ghalibaf AM, Rad MS, Rezaee R, Razavi BM, Hosseinzadeh H. Pharmacological effects of Safranal: an updated review. Iran J Basic Med Sci. 2023;26(10):1131.","journal-title":"Iran J Basic Med Sci"},{"key":"3302_CR6","doi-asserted-by":"publisher","first-page":"154170","DOI":"10.1016\/j.metabol.2020.154170","volume":"111","author":"A Mantovani","year":"2020","unstructured":"Mantovani A, Scorletti E, Mosca A, Alisi A, Byrne CD, Targher G. Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metabolism. 2020;111:154170.","journal-title":"Metabolism"},{"issue":"5","key":"3302_CR7","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1002\/hep.31150","volume":"71","author":"J Zhou","year":"2020","unstructured":"Zhou J, Zhou F, Wang W, Zhang XJ, Ji YX, Zhang P, et al. Epidemiological features of NAFLD from 1999 to 2018 in China. Hepatology. 2020;71(5):1851\u201364.","journal-title":"Hepatology"},{"key":"3302_CR8","doi-asserted-by":"crossref","unstructured":"Hormati A, Tooiserkany F, Mohammadbeigi A, Aliasl F, Dehnavi HM. Effect of an herbal product on the serum level of liver enzymes in patients with non-alcoholic fatty liver disease: A randomized, double-blinded, placebo-controlled trial. Iranian Red Crescent Medical Journal. 2019;21(7).","DOI":"10.5812\/ircmj.91024"},{"issue":"1","key":"3302_CR9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1472-6823-15-1","volume":"15","author":"U Ludwig","year":"2015","unstructured":"Ludwig U, Holzner D, Denzer C, Greinert A, Haenle MM, Oeztuerk S, et al. Subclinical and clinical hypothyroidism and non-alcoholic fatty liver disease: a cross-sectional study of a random population sample aged 18 to 65 years. BMC Endocr Disorders. 2015;15(1):1\u20137.","journal-title":"BMC Endocr Disorders"},{"issue":"1","key":"3302_CR10","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3109\/07853890.2014.966752","volume":"47","author":"E Suomela","year":"2015","unstructured":"Suomela E, Oikonen M, Virtanen J, Parkkola R, Jokinen E, Laitinen T, et al. Prevalence and determinants of fatty liver in normal-weight and overweight young adults. The Cardiovascular Risk in Young finns Study. Ann Med. 2015;47(1):40\u20136.","journal-title":"Ann Med"},{"issue":"9","key":"3302_CR11","first-page":"1275","volume":"43","author":"B Amirkalali","year":"2014","unstructured":"Amirkalali B, Poustchi H, Keyvani H, Khansari MR, Ajdarkosh H, Maadi M, et al. Prevalence of non-alcoholic fatty liver disease and its predictors in north of Iran. Iran J Public Health. 2014;43(9):1275.","journal-title":"Iran J Public Health"},{"key":"3302_CR12","doi-asserted-by":"crossref","unstructured":"Lankarani KB, Ghaffarpasand F, Mahmoodi M, Lotfi M, Zamiri N, Heydari ST et al. Non alcoholic fatty liver disease in southern Iran: a population based study. Hepat Monthly. 2013;13(5).","DOI":"10.5812\/hepatmon.9248"},{"issue":"1","key":"3302_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Reviews Gastroenterol Hepatol. 2018;15(1):11\u201320.","journal-title":"Nat Reviews Gastroenterol Hepatol"},{"issue":"4","key":"3302_CR14","doi-asserted-by":"publisher","first-page":"e1003100","DOI":"10.1371\/journal.pmed.1003100","volume":"17","author":"H Jarvis","year":"2020","unstructured":"Jarvis H, Craig D, Barker R, Spiers G, Stow D, Anstee QM, et al. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of population-based observational studies. PLoS Med. 2020;17(4):e1003100.","journal-title":"PLoS Med"},{"key":"3302_CR15","doi-asserted-by":"crossref","unstructured":"Rad MA, Goshayeshi L, Ghalibaf AAM, Majd HM, Soleimani G, Ahari RK. Helicobacter pylori Standard Triple Therapy Outcomes in Iranian Population: a Retrospective Population-based study in Mashhad, Northeast of Iran. Jundishapur J Microbiol. 2022;15(10).","DOI":"10.5812\/jjm-127842"},{"issue":"3","key":"3302_CR16","first-page":"149","volume":"7","author":"I Moghaddasifar","year":"2016","unstructured":"Moghaddasifar I, Lankarani KB, Moosazadeh M, Afshari M, Ghaemi A, Aliramezany M, et al. Prevalence of non-alcoholic fatty liver Disease and its related factors in Iran. Int J Organ Transpl Med. 2016;7(3):149\u201360.","journal-title":"Int J Organ Transpl Med"},{"issue":"5","key":"3302_CR17","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1002\/hep.28785","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Blissett D, Blissett R, Henry L, Stepanova M, Younossi Y, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology. 2016;64(5):1577\u201386.","journal-title":"Hepatology"},{"issue":"4","key":"3302_CR18","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1093\/aje\/kwx314","volume":"187","author":"H Poustchi","year":"2017","unstructured":"Poustchi H, Eghtesad S, Kamangar F, Etemadi A, Keshtkar A-A, Hekmatdoost A, et al. Prospective Epidemiological Research Studies in Iran (the PERSIAN Cohort Study): Rationale, objectives, and design. Am J Epidemiol. 2017;187(4):647\u201355.","journal-title":"Am J Epidemiol"},{"issue":"1","key":"3302_CR19","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1186\/s12889-020-09704-3","volume":"20","author":"F Tohidinezhad","year":"2020","unstructured":"Tohidinezhad F, Khorsand A, Zakavi SR, Rezvani R, Zarei-Ghanavati S, Abrishami M, et al. The burden and predisposing factors of non-communicable diseases in Mashhad University of Medical Sciences personnel: a prospective 15-year organizational cohort study protocol and baseline assessment. BMC Public Health. 2020;20(1):1637.","journal-title":"BMC Public Health"},{"issue":"5","key":"3302_CR20","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1053\/gast.2002.36572","volume":"123","author":"AJ Sanyal","year":"2002","unstructured":"Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology. 2002;123(5):1705\u201325.","journal-title":"Gastroenterology"},{"issue":"40","key":"3302_CR21","doi-asserted-by":"publisher","first-page":"6053","DOI":"10.3748\/wjg.v25.i40.6053","volume":"25","author":"G Ferraioli","year":"2019","unstructured":"Ferraioli G, Soares Monteiro LB. Ultrasound-based techniques for the diagnosis of liver steatosis. World J Gastroenterol. 2019;25(40):6053\u201362.","journal-title":"World J Gastroenterol"},{"issue":"3","key":"3302_CR22","first-page":"309","volume":"38","author":"N Keyfitz","year":"1966","unstructured":"Keyfitz N. Sampling variance of standardized mortality rates. Hum Biol. 1966;38(3):309\u201317.","journal-title":"Hum Biol"},{"issue":"1","key":"3302_CR23","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12876-018-0843-6","volume":"18","author":"BD Pardhe","year":"2018","unstructured":"Pardhe BD, Shakya S, Bhetwal A, Mathias J, Khanal PR, Pandit R, et al. Metabolic syndrome and biochemical changes among non-alcoholic fatty liver disease patients attending a tertiary care hospital of Nepal. BMC Gastroenterol. 2018;18(1):109.","journal-title":"BMC Gastroenterol"},{"issue":"5","key":"3302_CR24","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S2468-1253(19)30039-1","volume":"4","author":"J Li","year":"2019","unstructured":"Li J, Zou B, Yeo YH, Feng Y, Xie X, Lee DH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999\u20132019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019;4(5):389\u201398.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"3302_CR25","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.cgh.2020.04.067","volume":"19","author":"M Balakrishnan","year":"2021","unstructured":"Balakrishnan M, Patel P, Dunn-Valadez S, Dao C, Khan V, Ali H, et al. Women have a lower risk of nonalcoholic fatty liver disease but a higher risk of progression vs men: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2021;19(1):61\u201371. e15.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3302_CR26","doi-asserted-by":"crossref","unstructured":"Kwon Y-M, Oh S-W, Hwang S-s, Lee C, Kwon H, Chung GE. Association of Nonalcoholic Fatty liver Disease With Components of metabolic syndrome according to body Mass Index in Korean adults. Official J Am Coll Gastroenterol | ACG. 2012;107(12).","DOI":"10.1038\/ajg.2012.314"},{"issue":"1","key":"3302_CR27","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1053\/j.gastro.2010.09.038","volume":"140","author":"CD Williams","year":"2011","unstructured":"Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140(1):124\u201331.","journal-title":"Gastroenterology"},{"issue":"2","key":"3302_CR28","doi-asserted-by":"publisher","first-page":"112","DOI":"10.7326\/0003-4819-132-2-200001180-00004","volume":"132","author":"S Bellentani","year":"2000","unstructured":"Bellentani S, Saccoccio G, Masutti F, Croc\u00e8 LS, Brandi G, Sasso F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med. 2000;132(2):112\u20137.","journal-title":"Ann Intern Med"},{"issue":"1","key":"3302_CR29","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/sj.ijo.0802519","volume":"28","author":"TJ Hsiao","year":"2004","unstructured":"Hsiao TJ, Chen JC, Wang JD. Insulin resistance and ferritin as major determinants of nonalcoholic fatty liver disease in apparently healthy obese patients. Int J Obes. 2004;28(1):167\u201372.","journal-title":"Int J Obes"},{"issue":"5","key":"3302_CR30","doi-asserted-by":"publisher","first-page":"458","DOI":"10.5152\/tjg.2021.20641","volume":"32","author":"X Guan","year":"2021","unstructured":"Guan X, Zhang Q, Xing J, Chen S, Wu S, Sun X. Systolic blood pressure mediates body Mass Index and non-alcoholic fatty liver disease: a Population-based study. Turk J Gastroenterol. 2021;32(5):458\u201365.","journal-title":"Turk J Gastroenterol"},{"issue":"1","key":"3302_CR31","doi-asserted-by":"publisher","first-page":"19","DOI":"10.4103\/JMU.JMU_53_18","volume":"27","author":"UP Khanal","year":"2019","unstructured":"Khanal UP, Paudel B, Gurung G, Hu YS, Kuo CW. Correlational study of nonalcoholic fatty liver Disease diagnosed by Ultrasonography with lipid Profile and Body Mass Index in adult Nepalese Population. J Med Ultrasound. 2019;27(1):19\u201325.","journal-title":"J Med Ultrasound"},{"issue":"27","key":"3302_CR32","doi-asserted-by":"publisher","first-page":"e16018","DOI":"10.1097\/MD.0000000000016018","volume":"98","author":"YK Kim","year":"2019","unstructured":"Kim YK, Kwon OS, Her KH. The grade of nonalcoholic fatty liver disease is an independent risk factor for gallstone disease: an observational study. Med (Baltim). 2019;98(27):e16018.","journal-title":"Med (Baltim)"},{"issue":"3","key":"3302_CR33","doi-asserted-by":"publisher","first-page":"923","DOI":"10.4103\/jfmpc.jfmpc_243_18","volume":"8","author":"R Mansour-Ghanaei","year":"2019","unstructured":"Mansour-Ghanaei R, Mansour-Ghanaei F, Naghipour M, Joukar F. Biochemical markers and lipid profile in nonalcoholic fatty liver disease patients in the PERSIAN Guilan cohort study (PGCS), Iran. J Family Med Prim Care. 2019;8(3):923\u20138.","journal-title":"J Family Med Prim Care"},{"issue":"2","key":"3302_CR34","doi-asserted-by":"publisher","first-page":"85","DOI":"10.15171\/jcvtr.2017.14","volume":"9","author":"LR Cuenza","year":"2017","unstructured":"Cuenza LR, Razon TLJ, Dayrit JC. Correlation between severity of ultrasonographic nonalcoholic fatty liver disease and cardiometabolic risk among Filipino wellness patients. J Cardiovasc Thorac Res. 2017;9(2):85\u20139.","journal-title":"J Cardiovasc Thorac Res"},{"issue":"11","key":"3302_CR35","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/S2221-1691(13)60177-X","volume":"3","author":"DU Mahaling","year":"2013","unstructured":"Mahaling DU, Basavaraj MM, Bika AJ. Comparison of lipid profile in different grades of non-alcoholic fatty liver disease diagnosed on ultrasound. Asian Pac J Trop Biomed. 2013;3(11):907\u201312.","journal-title":"Asian Pac J Trop Biomed"},{"key":"3302_CR36","doi-asserted-by":"publisher","first-page":"942647","DOI":"10.3389\/fendo.2022.942647","volume":"13","author":"QR Song","year":"2022","unstructured":"Song QR, Liu SL, Ling QH, Gao QN, Yang RX, Chen SH, et al. Severity of nonalcoholic fatty liver disease is Associated with Cardiovascular outcomes in patients with prehypertension or hypertension: a community-based Cohort Study. Front Endocrinol (Lausanne). 2022;13:942647.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"3302_CR37","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/S0009-9260(05)80350-2","volume":"43","author":"AE Joseph","year":"1991","unstructured":"Joseph AE, Saverymuttu SH, al-Sam S, Cook MG, Maxwell JD. Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. Clin Radiol. 1991;43(1):26\u201331.","journal-title":"Clin Radiol"},{"issue":"16","key":"3302_CR38","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1056\/NEJMra011775","volume":"346","author":"P Angulo","year":"2002","unstructured":"Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346(16):1221\u201331.","journal-title":"N Engl J Med"},{"issue":"1","key":"3302_CR39","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s00535-014-0948-9","volume":"50","author":"K Nishioji","year":"2015","unstructured":"Nishioji K, Sumida Y, Kamaguchi M, Mochizuki N, Kobayashi M, Nishimura T, et al. Prevalence of and risk factors for non-alcoholic fatty liver disease in a non-obese Japanese population, 2011\u20132012. J Gastroenterol. 2015;50(1):95\u2013108.","journal-title":"J Gastroenterol"},{"issue":"22","key":"3302_CR40","doi-asserted-by":"publisher","first-page":"6821","DOI":"10.3748\/wjg.v20.i22.6821","volume":"20","author":"N Khov","year":"2014","unstructured":"Khov N, Sharma A, Riley TR. Bedside ultrasound in the diagnosis of nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20(22):6821\u20135.","journal-title":"World J Gastroenterol"},{"issue":"36","key":"3302_CR41","doi-asserted-by":"publisher","first-page":"12956","DOI":"10.3748\/wjg.v20.i36.12956","volume":"20","author":"MV Machado","year":"2014","unstructured":"Machado MV, Cortez-Pinto H. Non-alcoholic fatty liver disease: what the clinician needs to know. World J Gastroenterol. 2014;20(36):12956\u201380.","journal-title":"World J Gastroenterol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-024-03302-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-024-03302-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-024-03302-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T12:05:40Z","timestamp":1719403540000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-024-03302-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,26]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3302"],"URL":"https:\/\/doi.org\/10.1186\/s12876-024-03302-y","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,26]]},"assertion":[{"value":"9 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol for conducting the present study was approved by the ethics committee of Mashhad University of Medical Sciences, Mashhad, Iran (IR.MUM.MEDICA.REC.1397.750). The collection and analysis of the patients\u2019 information were done anonymously and using a code to prevent disclosure. Patients were free to leave the study at any time during the study, without the need to provide any explanation or reason. Informed consent was obtained from all participants of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"212"}}